Clinical Trial

Pembrolizumab in Locally Advanced Sinonasal Carcinoma

Study acronym: NeoPeSino
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will test the Safety and activity of pembrolizumab plus chemotherapy as neoadjuvant treatment in locally advanced sinonasal undifferentiated carcinoma (SNUC). Activity of neoadjuvant chemotherapy in locally advanced SNUC has been already demonstrated; the primary hypothesis is that the addition of pembrolizumab as neoadjuvant and adjuvant agent might confirm the results obtained with a combined treatment strategy including chemotherapy, decreasing the burden of treatment-related side effects.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-06-21; most recent amendment 2026-04-15.
Status change: Not Yet Recruiting → Recruiting 2025-04-10
Trial Details
NCT Number NCT05925491
Lead Sponsor Istituti Clinici Scientifici Maugeri SpA
Collaborators: Merck Sharp & Dohme LLC
Conditions Sinonasal Undifferentiated Carcinoma
Enrollment 28 participants
Start Date 2024-12-24
Primary Completion 2026-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-16